metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Lo más leído
Información de la revista

Lo más leído

5488
Evolving portal hypertension through Baveno VII recommendations
Manuel Mendizabal, Guilherme Grossi Lopes Cançado, Agustín Albillos
Ann Hepatol. 2024;29:101180
5488
Acceso a texto completo
4246
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, ... NAFLD Nomenclature consensus group
Ann Hepatol. 2024;29:101133
4246
Acceso a texto completo
3914
Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis
Shudi Li, Fei Duan, Suling Li, Baoping Lu
Ann Hepatol. 2024;29:101174
3914
Acceso a texto completo
3558
From NAFLD to MASLD: When metabolic comorbidity matters
Shan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei
Ann Hepatol. 2024;29:101281
3558
Acceso a texto completo
3222
Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells
Shuguang Pan, Ying Hu, Lang Gan, Jiejuan Lai, Ping Zheng, YuJun Zhang, Ling Shuai, Yan Jiang, ... Yu He
Ann Hepatol. 2024;29:101279
3222
Acceso a texto completo
3126
Alcohol-associated liver disease: Epidemiology and management
Helena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller
Ann Hepatol. 2024;29:101162
3126
Acceso a texto completo
2286
Why a pinch of zinc in liver disease matters
Kurt Grüngreiff, Dirk Reinhold, Wolfgang Maret
Ann Hepatol. 2024;29:101152
2286
Acceso a texto completo
2161
The burden of liver disease in Latin America
Luis Antonio Díaz, Marcela Villota-Rivas, Francisco Barrera, Jeffrey V. Lazarus, Marco Arrese
Ann Hepatol. 2024;29:101175
2161
Acceso a texto completo
1601
Schistosomiasis: A neglected cause of liver disease in the Philippines
Alexander M. Sy
Ann Hepatol. 2024;29:101166
1601
Acceso a texto completo
1501
From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.
Federico Piñero, Ezequiel Mauro, Paola Casciato, Alejandro Forner
Ann Hepatol. 2024;29:101185
1501
Acceso a texto completo
1357
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT
Jeremy Lee, Christopher J. Byrne, Paul N. Brennan, Iain MacPherson, Eleanor Dow, John F. Dillon
Ann Hepatol. 2024;29:101280
1357
Acceso a texto completo
1337
Pathophysiology of ascites: The importance of the intestine. A surgical contribution to the understanding of a medical problem
Gabriel E. Gondolesi, Carolina Rumbo, Leonardo Montes, Lucia Novellis, Diego Ramisch, Ariel Riquelme Henríquez, Mariana Ortega, Federico Viano, ... Héctor Solar
Ann Hepatol. 2024;29:101498
1337
Acceso a texto completo
1252
Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care
Inah Marie C. Aquino, Devis Pascut
Ann Hepatol. 2024;29:101176
1252
Acceso a texto completo
1202
Prevalence of occult hepatitis B virus infection and characterisation of hepatitis B surface antigen mutants among adults in western Croatia
Marina Bubonja-Šonje, Dolores Peruč, Maja Abram, Bojana Mohar-Vitezić
Ann Hepatol. 2024;29:101156
1202
Acceso a texto completo
1131
From NAFLD to MASLD: Promise and pitfalls of a new definition
Kenneth Cusi, Zobair Younossi, Michael Roden
Ann Hepatol. 2024;29:101179
1131
Acceso a texto completo
1110
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
Maria Jimenez Ramos, Timothy J. Kendall, Ignat Drozdov, Jonathan A. Fallowfield
Ann Hepatol. 2024;29:101278
1110
Acceso a texto completo
1037
Global prevalence of occult HBV infection in children and adolescents: A systematic review and meta-analysis
Jiaying Wu, Jiayao He, Hongmei Xu
Ann Hepatol. 2024;29:101158
1037
Acceso a texto completo
1000
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018
Tongtong Wang, Yuzhi Xi, Annaswamy Raji, Michael Crutchlow, Gail Fernandes, Samuel S Engel, Xiao Zhang
Ann Hepatol. 2024;29:101154
1000
Acceso a texto completo
994
NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study
Renling Yao, Sufang Lu, Ruifei Xue, Jian Wang, Yuanwang Qiu, Yuxin Chen, Jiacheng Liu, Li Zhu, ... Chao Wu
Ann Hepatol. 2024;29:101155
994
Acceso a texto completo
961
Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?
Caecilia HC Sukowati, Korri El-Khobar, Chyntia Olivia Maurine Jasirwan, Juferdy Kurniawan, Rino Alvani Gani
Ann Hepatol. 2024;29:101153
961
Acceso a texto completo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos